




RealRate

PHARMACEUTICAL 2026

Lexaria Bioscience Corp
Rank 160 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lexaria Bioscience Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexaria Bioscience Corp compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Lexaria Bioscience Corp is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is 97%, being 133% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	3,468
Cost of Goods Sold	2.7
Intangible Assets	0
Liabilities, Current	1,493
Liabilities, Non-Current	79
Other Assets	479
Other Compr. Net Income	-41
Other Expenses	0
Other Liabilities	0
Other Net Income	-31
Other Revenues	706
Property and Equipment	228
Research and Development	8,239
Selling, General and Administrative Expense	4,345

Output Variable	Value in 1000 USD
Assets	4,175
Liabilities	1,572
Expenses	12,587
Revenues	706
Stockholders Equity	2,603
Net Income	-11,911
Comprehensive Net Income	-11,932
BaseVar	9,556
ECR before Limited Liability	-218%
Economic Capital Ratio	97%